// App-Quantinova.ai

TPS2608 : A Phase Ib, Open-Label, Multi-Center Study to Assess the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of AZD1775 Monotherapy in Patients with Advanced Solid Tumors: Expansion Cohorts.

Researchers

Presenter

  • Todd Michael Bauer

Principal Investigators

  • Suzanne Fields Jones

  • Carol Greenlees

  • Carl Cook

  • Philip John Jewsbury

  • Ganesh Mugundu

  • Tim French

  • Andrew J Pierce

  • Mark J. O'Connor

  • Naomi Laing

  • J Carl Barrett

  • Dawn Michelle Stults

  • Melissa Lynne Johnson

  • J. Thaddeus Beck

  • Kathleen N. Moore

  • Jeffrey R. Infante

  • Howard A. Burris

  • David R. Spigel

Medical Centers

  • Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN

  • Sarah Cannon Research Institute, Nashville, TN

  • Sarah Cannon Research Institute, London, United Kingdom

  • AstraZeneca, Boston, MA

  • AstraZeneca, Macclesfield, United Kingdom

  • Highlands Oncology Group, Fayetteville, AR

  • University of Oklahoma Health Sciences Center, Oklahoma City, OK

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

  • Small cell lung cancer

  • Triple-negative breast cancer

Biomarkers

  • MYCN proto-oncogene, bHLH transcription factor

  • cMYC

Drug/Treatment

  • AZD-1775

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • Open Label

  • Multicenteric

Phase

  • I

Study Id's

  • NCT02482311

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved